Inhibition of survivin using shRNA in the primary ALL cell LAX7R eradicated minimal residual disease (MRD) in combination with chemotherapy (vincristine, dexamethasone, and l-asparaginase [VDL] for Ph negative ALL or nilotinib, a tyrosine kinase inhibitor, for Ph positive ALL) [91]. Here, BIRC5 is linked to acute lymphoblastic leukemia.